Scinai Biopharma Services names Eilon Elmalem head of Yavne facility May 20, 2026 07:00AM
Scinai completes reorganization, creates dedicated CDMO subsidiary Apr 6, 2026 07:01AM
Scinai receives expanded funding for robotic manufacturing platform Feb 25, 2026 08:12AM
Scinai reports revenue growth amid mixed nine-month results Dec 2, 2025 08:55AM
Scinai receives $246,000 Israel grant for manufacturing expansion Oct 6, 2025 07:31AM


Sep 22, 2025 10:50AM Scinai Immunotherapeutics (SCNI) files for 4.8M share offering by selling stockholders
Jul 29, 2025 07:16AM Scinai publishes peer-reviewed data supporting PC111 therapy for skin diseases
Jun 5, 2025 09:01AM Scinai Immunotherapeutics (SCNI) Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Mar 27, 2025 09:27AM Scinai enters binding option agreement to acquire Pincell srl
Mar 5, 2025 07:32AM Scinai Immunotherapeutics (SCNI) Announces $10 Million Standby Equity Purchase Agreement
Aug 29, 2024 06:32AM Scinai Immunotherapeutics (SCNI) Regains Nasdaq Compliance
Aug 20, 2024 09:30AM Scinai Immunotherapeutics (SCNI) Enters $2M Private Equity Commitment Agreement
Aug 13, 2024 07:55AM Scinai (SCNI) Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Jul 15, 2024 07:02AM Scinai Immunotherapeutics (SCNI) announces promising results in an in-vivo proof-of-concept psoriatic human skin model
Jul 3, 2024 09:33AM Scinai Immunotherapeutics (SCNI) Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Jul 2, 2024 08:15AM Scinai Immunotherapeutics (SCNI) Publishes Q1 2024 Financial Results and Provides Business Update
Jun 13, 2024 07:01AM Scinai Immunotherapeutics (SCNI) Receives LoI from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity